Author:
Orkin Chloe,Oka Shinichi,Philibert Patrick,Brinson Cynthia,Bassa Ayesha,Gusev Denis,Degen Olaf,García Juan González,Morell Enrique Bernal,Tan Darrell H S,D'Amico Ronald,Dorey David,Griffith Sandy,Thiagarajah Shanker,St Clair Marty,Van Solingen-Ristea Rodica,Crauwels Herta,Ford Susan L,Patel Parul,Chounta Vasiliki,Vanveggel Simon,Cutrell Amy,Van Eygen Veerle,Vandermeulen Kati,Margolis David A,Smith Kimberly Y,Spreen William R
Funder
ViiV Healthcare
Janssen Research and Development
Subject
Virology,Infectious Diseases,Immunology,Epidemiology
Reference29 articles.
1. Zidovudine approved by FDA for treatment of AIDS;Clin Pharm,1987
2. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials
3. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies;Llibre;Lancet,2018
4. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study
5. Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks’ follow-up;Lee;PLoS One,2014
Cited by
77 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献